<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648284</url>
  </required_header>
  <id_info>
    <org_study_id>104243</org_study_id>
    <secondary_id>Avandia OB</secondary_id>
    <nct_id>NCT00648284</nct_id>
  </id_info>
  <brief_title>Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects</brief_title>
  <official_title>An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the total CV risk in patients with type 2
      diabetes and also to assess the impact of rosiglitazone in the total CV risk and the
      parameters of metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>1100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>CV Risk</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA
             for better control of their condition

          -  Have signed informed consent

        Exclusion Criteria:

          -  Patients with ALT &gt; 2.5x the normal value

          -  With heart failure symptoms

          -  With diagnosis of angina pectoris or stable angina demanding continuous treatment with
             nitrates

          -  With recent myocardial infarction (&lt;6 months)

          -  With severe renal disfunction

          -  Pregnant or lactating or planned to be pregnant during the study

          -  Under investigational drug treatment

          -  Alcoholic or drug abuser
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>October 13, 2008</last_update_submitted>
  <last_update_submitted_qc>October 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>CV risk</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>AVANDIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

